Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Voyager Therapeutics Inc VYGR

Healthcare Biotechnology
Voyager Therapeutics, Inc. is a biotechnology company focused on advancing neurogenetic medicines. The Company’s pipeline includes programs for Alzheimer’s disease, amyotrophic lateral sclerosis (ALS), Parkinson’s disease, and multiple other diseases of the central nervous system. Many of its programs are derived from its TRACER AAV capsid discovery platform, which is used to generate novel... see more

Recent & Breaking News (NDAQ:VYGR)

Voyager Therapeutics Reports Second Quarter 2023 Financial and Operating Results

GlobeNewswire August 3, 2023

Voyager Therapeutics to Present at the Canaccord Genuity Growth Conference

GlobeNewswire August 2, 2023

Voyager Therapeutics Announces Second Quarter 2023 Conference Call and Webcast

GlobeNewswire July 27, 2023

Voyager Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire July 11, 2023

Voyager Therapeutics Announces Appointment of Jacquelyn Fahey Sandell as Chief Legal Officer

GlobeNewswire July 10, 2023

Voyager Therapeutics to Present at the Jefferies Healthcare Conference

GlobeNewswire June 1, 2023

Voyager Therapeutics Presents Robust, Multi-Species Results from Preclinical Studies of IV-Delivered, TRACER(TM)-Generated Novel Capsids at the ASGCT 26th Annual Meeting

GlobeNewswire May 18, 2023

Voyager Therapeutics Reports First Quarter 2023 Financial and Operating Results

GlobeNewswire May 9, 2023

Voyager Therapeutics Announces Appointment of George Scangos, Ph.D., to Board of Directors

GlobeNewswire May 9, 2023

Voyager Therapeutics Announces Multiple Data Presentations at the American Society of Gene and Cell Therapy 26th Annual Meeting

GlobeNewswire May 2, 2023

Voyager Therapeutics Announces First Quarter 2023 Conference Call and Webcast

GlobeNewswire May 2, 2023

Voyager Therapeutics Presents New Data Supporting Tau Antibody Program for Alzheimer's Disease and GBA1 Gene Therapy Program for Parkinson's Disease at the AD/PD(TM) Conference

GlobeNewswire March 28, 2023

Voyager Therapeutics Reports Fourth Quarter and Full Year 2022 Financial and Operating Results

GlobeNewswire March 7, 2023

Voyager Therapeutics to Receive $25 Million Payment for License of Next-Generation AAV Capsids for Multiple Neurologic Disease Targets

GlobeNewswire March 6, 2023

Voyager Therapeutics Announces Fourth Quarter and Full Year 2022 Conference Call and Webcast

GlobeNewswire February 28, 2023

Voyager Therapeutics to Participate in Upcoming Investor Conferences

GlobeNewswire February 9, 2023

Voyager Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire January 24, 2023

Neurocrine Biosciences and Voyager Therapeutics Enter Strategic Collaboration for Development and Commercialization of Voyager's GBA1 Program and Other Next-Generation Gene Therapies for Neurological Diseases

GlobeNewswire January 9, 2023

Voyager Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference

GlobeNewswire January 4, 2023

Voyager Therapeutics Appoints Grace E. Colón, Ph.D., to its Board of Directors

GlobeNewswire December 14, 2022